MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TVRD had $770K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$770K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-5,527 -5,412
Depreciation and amortization expense
24 47
Stock-based compensation expense
339 707
Change in fair value of convertible notes
0 -7,810
Non-cash lease expense
18 35
Accretion of discounts on short-term investments
25 141
Interest accrued on convertible notes
0 651
Prepaid expenses and other assets
-153 1,717
Accounts payable and accrued expenses
787 132
Operating lease liabilities
-26 -49
Net cash used in operating activities
-4,257 -13,557
Purchases of short-term investments
0 31,486
Maturities of short-term investments
5,349 11,053
Net cash used in investing activities
5,349 -20,433
Cash acquired in connection with the merger
0 24,992
Payments for merger transaction costs
429 2,392
Proceeds from exercise of stock options
107 424
Net cash provided by (used in) financing activities
-322 23,024
Net decrease in cash and cash equivalents
770 -10,966
Cash and cash equivalents at beginning of period
31,614 -
Cash and cash equivalents at end of period
21,418 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Tvardi Therapeutics, Inc. (TVRD)

Tvardi Therapeutics, Inc. (TVRD)